



Title	Extensive Accumulation of Influenza Virus NS1 Protein in the Nuclei Causes Effective Viral Growth in Vero Cells
Author(s)	Ozaki, Hiroichi; Kida, Hiroshi
Citation	Microbiology and Immunology, 51(5), 577-580
Issue Date	2007
Doc URL	http://hdl.handle.net/2115/26122
Type	article (author version)
File Information	MAI51-5.pdf



[Instructions for use](#)

- 1 Editor-Communicated Paper
- 2 Note
- 3 (a) Extensive accumulation of influenza virus NS1 protein in the nuclei causes effective viral growth
- 4 in VERO cells
- 5 (b) Hiroichi Ozaki^{1*} and Hiroshi Kida²
- 6 (c) ¹ Creative Research Initiative ‘Sousei’, Hokkaido University, Sapporo 001-0021, Japan,
- 7 ² Department of Disease Control, Hokkaido University Graduate School of Veterinary Medicine,
- 8 Sapporo 060-0818, Japan
- 9
- 10 (d) *Corresponding author; Hiroichi Ozaki,
- 11 Tel: +81-11-706-9236, Fax: +81-11-706-9294
- 12 E-mail: ikazo-h@cris.hokudai.ac.jp
- 13
- 14 (e) Running head; NS1 LOCALIZATION IN VERO CELLS
- 15 (f) Key words: influenza virus, NS1, nuclear localization
- 16 (g) Editor-Communicated Paper, Animal RNA virus

1 Abstract.

2 We previously showed that modified A/Puerto Rico/8/34 (PR8) influenza master strain
3 had improved viral rescue and growth properties in African green monkey kidney (Vero) cell line by
4 introducing NS gene of Vero-adapted A/England/1/53 (vaEng53). In the present study, it was found
5 that the NS1 protein derived from vaEng53 was extensively accumulated in the nuclei than that of
6 PR8. This accumulation was caused by 7 amino acid differences in C-terminal region of NS1 protein.
7 These results suggest that specific accumulation of NS1 protein may contribute to efficient viral
8 replication in Vero cells.

9

1 For the control of influenza, it is required the monitoring of virus infection in birds and
2 mammals and the development of improved antiviral therapies and vaccines. The most widely used
3 influenza vaccines are those made from subunits of inactivated viruses propagated in chicken
4 embryonated eggs. Although routinely used to prepare influenza vaccines and diagnostic reagents,
5 problems include the lack of reliable year-round supplies of high-quality eggs, the possible presence
6 of pathogens, and the low growth of influenza virus in summer eggs (10). In order to resolve this
7 problem, we demonstrated that well-characterized African green monkey kidney (Vero) cell line was
8 available for cell-based vaccine production with reverse genetics as an alternative method. The
9 nonstructural (NS) protein gene derived from Vero-adapted virus contributed effective viral growth
10 in early stage of infection (11). In the present study, we investigated the relationship between
11 localization of NS1 protein and growth kinetics of virus with mutant NS genes in Vero cells.

12 The plasmids carrying the eight gene segments of PR8 (H1N1) virus (pHW191 to
13 pHW198) and plasmid carrying NS gene derived from Vero-adapted A/England/1/53 (H1N1)
14 (vaEng53) (pHW/vaEng53-NS) (11) were used for the rescue of mutant viruses. Chimeric NS genes
15 were constructed and modified by swapping first half and second half of *NcoI* or *SspI* digested
16 fragments between PR8 and vaEng53 NS genes, respectively (Fig.1). Virus rescue and viral growth
17 kinetics in Vero cells was performed by following the method previously described (11). Nuclear
18 localization of each mutant NS1 protein was detected by immunofluorescent assay (6). Briefly, the
19 viruses with different mutant NS gene were inoculated on confluent Vero cells with a multiplicity of
20 infection (MOI) of 1 pfu/cell. Three, five, and nine hours post infection, cells were fixed with
21 methanol and reacted with anti-NS1 monoclonal antibody (3). NS1 protein was detected with Alexa
22 Fluor-488 goat anti-mouse IgG antibody (Invitrogen).

23 To confirm the effect of the replacement of the NS gene segment in PR8 on subsequent
24 virus amplification in Vero cells, we tested triplicate samples of near-confluent Vero cells with PR8

1 and PR8/vaEng53-NS at a low MOI (=0.01) and monitored virus replication by assaying culture
2 supernatants every 12 h. As shown in Fig. 2, vaEng53 NS gene was confirmed to contribute to the
3 effective growth in Vero cells in early stage of virus replication. We, then, constructed carrying
4 chimeric NS genes swapped the *NcoI* fragments between PR8 and vaEng53 NS genes in order to
5 determine which region of the NS1 protein would be required for growth in early stage (Fig. 1). The
6 mutant PR8 viruses with each chimeric NS gene were applied to assess the growth kinetics as above.
7 The mutant PR8 including PE1-NS chimeric NS gene showed similar growth kinetics to that of
8 PR8/vaEng53-NS. On the other hand, the growth of virus with EP1-NS chimeric NS gene was
9 identical with that of PR8 (Fig. 2a). Moreover, to narrow the responsible region down for the
10 phenomenon, two more chimeric NS genes were constructed by swapping *SspI* fragments (Fig. 1).
11 Growth kinetics curves showed that PE2-NS gene gave a contribution for rapid replication of virus
12 in Vero cells (Fig. 2b). These results indicate that near C-terminal region of NS1 protein is
13 responsible for the rapid growth of the virus in Vero cells.

14 Amino acid alignment analysis revealed 15 amino acid differences on the NS1 protein
15 between PR8 and vaEng53 (Fig. 1). Since 8 out of 15 amino acids did not affect to viral growth in
16 Vero cells, the remaining 7 amino acid differences would be responsible to this phenomenon. We,
17 then, focused on the nuclear localizing signal 2 (NLS2), PKQKRK motif (7) of the NS1 protein
18 because the RNA binding domain, NLS1, and the effector domain (described below and Fig. 1) were
19 respectively common between both NS1 proteins. One amino acid difference was found in NLS2
20 between PR8 (PKQKRE) and vaEng53 (PKQKRK) NS1 proteins. To assess the localization of the
21 NS1 protein in Vero cells, the mutant viruses were inoculated in Vero cells and NS1 protein was
22 detected by immunofluorescence assay in different time points. As shown in Fig. 3, the NS1 protein
23 derived from vaEng53 NS gene was detected in three hours post inoculation in Vero cells but not
24 that of PR8. Five hours post inoculation, almost all of NS1 protein from vaEng53 NS gene was

1 accumulated in the nuclei of the cells with stronger signal than that of PR8. Four more hours later,
2 the NS1 protein of PR8 was detected both in the nuclei and cytoplasm. Interestingly, NS1 protein
3 from vaEng53 NS gene was still observed in the nuclei with strong signal at the same time point. In
4 addition, PE1-NS1 and PE2-NS1 proteins were also detected similarly in the nuclei as that of
5 vaEng53 NS gene (data not shown).

6 In the present study, we demonstrated that 7 amino acid substitutions in C-terminal region
7 of NS1 protein from vaEng53 were responsible for the growth efficiency in Vero cells. Among these
8 substitutions, one amino acid substitution detected in NLS2 motif may have a possibility to be
9 related to the specific accumulation in the nuclei. The NS1 protein of influenza A virus regulates two
10 post transcriptional events in the nucleus: the inhibition of the nuclear export of poly (A)-containing
11 cellular and viral mRNAs, and the inhibition of pre-mRNA splicing (1, 5, 9, 12-14). These nuclear
12 functions are caused by an RNA-binding domain near N-terminal, and an effector domain in the
13 carboxyl half of the molecule interacting with cellular nuclear proteins (12). Then, viral polymerase
14 is able to generate capped primer effectively. Thus, specific accumulation of the NS1 protein in the
15 nuclei may cause increased viral replication in Vero cells. In addition, NS1 protein represses the host
16 cell antiviral response by multiple mechanisms. These mechanisms include the inhibition of the
17 interferon-inducible double stranded RNA activated kinase PKR (protein kinase RNA-regulated) (2,
18 8, 17) and the blocking of interferon- β production by preventing NF- κ B (18), interferon-regulatory
19 factor (IRF) 3 (16), and IRF7 activation (15). It is unlikely, however, that antiviral NS1 functions are
20 involved in efficiency of viral growth in Vero cells, because Vero cells are defective in the
21 production of interferon (4).

22 For cell-based vaccine production, it is required to choose a suitable backbone considering
23 the properties of each fragment like NS gene in this study. Although it is unknown that the influence
24 of the remaining 6 amino acid substitutions in NS1 protein and nuclear exporting protein coded in

- 1 the same gene, the present study demonstrates that NS gene is a critical factor for controlling viral
- 2 growth in Vero cells. It is important to understand the mechanisms how the NS gene derived from
- 3 Vero-adapted strain affects on the viral replication in Vero cells.

1 Acknowledgements.

2 These studies were supported by Grants-in-Aid for Scientific Research (17780224) from
3 the Ministry of Education, Culture, Sports, Science and Technology. We are grateful to Dr. R.
4 Webby for his technical advice.

1 Figure legends.

2 Figure 1.

3 Schematic diagram for construction of chimeric NS1 proteins. Dot lines are shown as fragment
4 swapping points by digestion of *NcoI* or *SspI* site, respectively. Arrows indicate the points of amino
5 acid difference on NS1 protein. Three black bars indicate RNA binding domain and nuclear
6 localizing signal 1 (NLS1), effector domain, and NLS2, respectively.

7

8 Figure 2.

9 The growth characteristics of PR8 and PR8 with chimeric NS gene in Vero cells. Vero cells were
10 inoculated with 0.01 MOI of each virus. Panel (a) shows the growth kinetics of PR8 (closed
11 diamond) vs PR8 with vaEng53-NS (closed square), PE1-NS (open diamond), or EP1-NS (open
12 circle) gene. Panel (b) shows the growth kinetics of PR8 (closed diamond) vs PR8 with vaEng53-NS
13 (closed square), PE2-NS (open diamond), or EP2-NS (open circle) gene. Each plot is shown as
14 average of 3 independent experiments.

15

16 Figure 3.


17 Nuclear localization of NS1 protein in Vero cells. Vero cells were inoculated with 1 MOI of PR8
18 (a-c) or PR8/vaEng53-NS (d-f). Cells were fixed at 3 hours (a, d), 5 hours (b, e), and 9 hours (c, f)
19 post inoculation and NS1 protein was detected by indirect immunofluorescence using mouse
20 anti-NS1 monoclonal antibody. Magnification is 1:400.

1 References.

2

- 3 1) Alonso-Caplen, F.V., Nemeroff, M.E., Qiu, Y., and Krug, R.M. 1992. Nucleocytoplasmic
4 transport: the influenza virus NS1 protein regulates the transport of spliced NS2 mRNA and
5 its precursor NS1 mRNA. *Genes Dev.* **6**:255-267.
- 6 2) Bergmann, M., Garcia-Sastre, A., Carnero, E., Pehamberger, H., Wolff, K., Palese, P., and
7 Muster, T. 2000. Influenza virus NS1 protein counteracts PKR-mediated inhibition of
8 replication. *J. Virol.* **74**:6203-6206.
- 9 3) Brown, L.E., Hinshaw, V.S., and Webster, R.G. 1983. Antigenic variation in the influenza A
10 virus nonstructural protein, NS1. *Virology* **130**:134-143.
- 11 4) Desmyter, J., Melnick, J.L., and Rawls, W.E. 1968. Defectiveness of interferon production
12 and of rubella virus interference in a line of African green monkey kidney cells (Vero). *J.*
13 *Virol.* **2**:955-961.
- 14 5) Fortes, P., Beloso, A., and Ortin, J. 1994. Influenza virus NS1 protein inhibits pre-mRNA
15 splicing and blocks mRNA nucleocytoplasmic transport. *EMBO J.* **13**:704-712.
- 16 6) Greenspan, D., Krystal, M., Nakada, S., Arnheiter, H., Lyles, D.S., and Palese, P. 1985.
17 Expression of influenza virus NS2 nonstructural protein in bacteria and localization of NS2 in
18 infected eucaryotic cells. *J. Virol.* **54**:833-843.
- 19 7) Greenspan, D., Palese, P., and Krystal, M. 1988. Two nuclear location signals in the influenza
20 virus NS1 nonstructural protein. *J. Virol.* **62**:3020-3026.
- 21 8) Hatada, E., Saito, S., and Fukuda, R. 1999. Mutant influenza viruses with a defective NS1
22 protein cannot block the activation of PKR in infected cells. *J. Virol.* **73**:2425-2433.
- 23 9) Lu, Y., Qian, X.Y., and Krug, R.M. 1994. The influenza virus NS1 protein: a novel inhibitor
24 of pre-mRNA splicing. *Genes Dev.* **8**:1817-1828.
- 25 10) Monto, A.S., Maassab, H.F., and Bryan, E.R. 1981. Relative efficacy of embryonated eggs
26 and cell culture for isolation of contemporary influenza viruses. *J. Clin. Microbiol.*
27 **13**:233-235.
- 28 11) Ozaki, H., Govorkova, E.A., Li, C., Xiong, X., Webster, R.G., and Webby, R.J. 2004.
29 Generation of high-yielding influenza A viruses in African green monkey kidney (Vero) cells

- 1 by reverse genetics. *J. Virol.* **78**:1851-1857.
- 2 12) Qian, X.Y., Alonso-Caplen, F., and Krug, R.M. 1994. Two functional domains of the
3 influenza virus NS1 protein are required for regulation of nuclear export of mRNA. *J. Virol.*
4 **68**:2433-2441.
- 5 13) Qiu, Y. and Krug, R.M. 1994. The influenza virus NS1 protein is a poly(A)-binding protein
6 that inhibits nuclear export of mRNAs containing poly(A). *J. Virol.* **68**:2425-2432.
- 7 14) Qiu, Y., Nemeroff, M., and Krug, R.M. 1995. The influenza virus NS1 protein binds to a
8 specific region in human U6 snRNA and inhibits U6-U2 and U6-U4 snRNA interactions
9 during splicing. *RNA.* **1**:304-316.
- 10 15) Smith, E.J., Marie, I., Prakash, A., Garcia-Sastre, A., and Levy, D.E. 2001. IRF3 and IRF7
11 phosphorylation in virus-infected cells does not require double-stranded RNA-dependent
12 protein kinase R or Ikappa B kinase but is blocked by Vaccinia virus E3L protein. *J. Biol.*
13 *Chem.* **276**:8951-8957.
- 14 16) Talon, J., Horvath, C.M., Polley, R., Basler, C.F., Muster, T., Palese, P., and Garcia-Sastre, A.
15 2000. Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1
16 protein. *J. Virol.* **74**:7989-7996.
- 17 17) Tan, S.L. and Katze, M.G. 1998. Biochemical and genetic evidence for complex formation
18 between the influenza A virus NS1 protein and the interferon-induced PKR protein kinase. *J.*
19 *Interferon Cytokine Res.* **18**:757-766.
- 20 18) Wang, X., Li, M., Zheng, H., Muster, T., Palese, P., Beg, A.A., and Garcia-Sastre, A. 2000.
21 Influenza A virus NS1 protein prevents activation of NF-kappaB and induction of alpha/beta
22 interferon. *J. Virol.* **74**:11566-11573.
- 23
24
25



Ozaki and Kida Fig. 1

